0JBU Stock Overview
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of curative therapeutics.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 2/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Intellia Therapeutics, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$21.43 |
52 Week High | US$46.91 |
52 Week Low | US$21.34 |
Beta | 1.8 |
1 Month Change | -22.82% |
3 Month Change | -16.01% |
1 Year Change | -41.87% |
3 Year Change | -71.79% |
5 Year Change | 17.40% |
Change since IPO | -13.29% |
Recent News & Updates
Recent updates
Shareholder Returns
0JBU | GB Biotechs | GB Market | |
---|---|---|---|
7D | -12.0% | -2.3% | -0.7% |
1Y | -41.9% | -29.4% | -1.8% |
Return vs Industry: 0JBU underperformed the UK Biotechs industry which returned -29.4% over the past year.
Return vs Market: 0JBU underperformed the UK Market which returned -1.8% over the past year.
Price Volatility
0JBU volatility | |
---|---|
0JBU Average Weekly Movement | 9.2% |
Biotechs Industry Average Movement | 7.5% |
Market Average Movement | 4.8% |
10% most volatile stocks in GB Market | 11.5% |
10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: 0JBU's share price has been volatile over the past 3 months.
Volatility Over Time: 0JBU's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of UK stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2014 | 526 | John Leonard | www.intelliatx.com |
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of curative therapeutics. The company’s in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease. It also focusses on programs comprising hemophilia A and hemophilia B; and research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases.
Intellia Therapeutics, Inc. Fundamentals Summary
0JBU fundamental statistics | |
---|---|
Market cap | US$2.06b |
Earnings (TTM) | -US$481.19m |
Revenue (TTM) | US$36.28m |
56.7x
P/S Ratio-4.3x
P/E RatioIs 0JBU overvalued?
See Fair Value and valuation analysisEarnings & Revenue
0JBU income statement (TTM) | |
---|---|
Revenue | US$36.28m |
Cost of Revenue | US$435.07m |
Gross Profit | -US$398.79m |
Other Expenses | US$82.40m |
Earnings | -US$481.19m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -4.99 |
Gross Margin | -1,099.36% |
Net Profit Margin | -1,326.51% |
Debt/Equity Ratio | 0% |
How did 0JBU perform over the long term?
See historical performance and comparison